G. Safont

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
G Safont, G. Safont, Gemma Safont
Publication record
51 papers · 891 citations · H-index 15

PAPERS

Predictive Value of C-Reactive Protein and Hematologic Ratios for Metabolic Syndrome in Schizophrenia.
20260 citationsauthor #9
Intestinal permeability biomarkers in patients with schizophrenia: Additional support for the impact of lifestyle habits
20248 citationsauthor #9
Impact of sleep on clinical outcomes in a cohort of patients with bipolar disorder
20241 citationsauthor #8
Impact of cognitive reserve in clinical, neurocognitive and lifestyle factors in early stages of psychosis and chronic schizophrenia.
20243 citationsauthor #8
Maternity in women with schizophrenia and schizoaffective disorder.
20237 citationsauthor #1
Intestinal permeability and low-grade chronic inflammation in schizophrenia: A multicentre study on biomarkers. Rationale, objectives, protocol and preliminary results.
20235 citationsauthor #3
From gut to brain: A network model of intestinal permeability, inflammation, and psychotic symptoms in schizophrenia.
20239 citationsauthor #10
Sex and substance use in first episode psychosis: impact on clinical symptoms, psychosocial functioning and cognitive performance
20223 citationsauthor #1
Cognitive reserve predicts metabolic syndrome risk in schizophrenia
20220 citationsauthor #6
Assessing cognitive reserve outcomes and biomarkers in first episode of psychosis: Rationale, objectives, protocol and preliminary results of the CRASH Project.
20220 citationsauthor #9
P.0148 Sex differences in first episode of psychosis with or without substance use history
20210 citationsauthor #3
P.0153 Association between negative and cognitive symptoms and apolipoprotein a1 and b plasma levels in schizophrenia
20210 citationsauthor #7
Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein levels and metabolic status in patients with a bipolar disorder
202110 citationsauthor #4
Spanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder.
20211 citationsauthor #23
S47. A MULTICENTER STUDY OF COGNITIVE RESERVE IN FIRST-EPISODE PYCHOSIS
20200 citationsauthor #9
P.530 Intestinal permeability and low-grade chronic inflammation in schizophrenia: do they influence cognition and cognitive reserve?
20200 citationsauthor #5
A Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: A Protocol Design
20205 citationsauthor #9
Sex differences in bipolar disorder: Impact of lifetime cannabis use on clinical course, functioning, and quality of life in bipolar disorder.
20209 citationsauthor #7
A clinical staging model for bipolar disorder: longitudinal approach
202025 citationsauthor #6
M176. INTESTINAL PERMEABILITY AND LOW-GRADE CHRONIC INFLAMMATION IN SCHIZOPHRENIA: DO THEY INFLUENCE COGNITION AND COGNITIVE RESERVE?
20200 citationsauthor #5
Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
202028 citationsauthor #9
Sexual Dysfunction and Mood Stabilizers in Long-Term Stable Patients With Bipolar Disorder.
202013 citationsauthor #7
1 kW cw fiber-coupled diode laser with enhanced brightness
20202 citationsauthor #4
Corrigendum: A Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: A Protocol Design
20200 citationsauthor #9
P.550 The impact of cognitive reserve in first-episode pychosis: a multicenter study
20200 citationsauthor #10
Are plasma 25-hydroxyvitamin D and retinol levels and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?
20192 citationsauthor #4
Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability
201944 citationsauthor #22
Are altered plasma vitamin D, vitamin A and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?
20190 citationsauthor #3
Classification of patients with bipolar disorder using k-means clustering
201941 citationsauthor #3
Sleep disturbances, functioning, and quality of life in euthymic patients with bipolar disorder.
201829 citationsauthor #5
Gender differences in C-reactive protein and homocysteine modulation of cognitive performance and real-world functioning in bipolar disorder.
201829 citationsauthor #3
Are altered plasma vitamin D, vitamin A and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?
20180 citationsauthor #3
Are affective temperaments determinants of quality of life in euthymic patients with bipolar disorder?
201811 citationsauthor #5
1st International Experts’ Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation
201846 citationsauthor #16
Physical Health in Early and Late Stages of Bipolar Disorder
20170 citationsauthor #7
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
2017208 citationsauthor #43
Impact of sleep disturbance in functioning and quality of life in euthymic patients with bipolar disorder
20160 citationsauthor #3
Differential serum acute-phase biomarker profile in schizophrenia and bipolar disorder
20161 citationsauthor #4
Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?
201528 citationsauthor #2
Disability in bipolar I disorder: the 36-item World Health Organization Disability Assessment Schedule 2.0.
201551 citationsauthor #12
The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients
201346 citationsauthor #6
P-1294 - Utility of the World Health Organization Disability Assessment Schedule ii in Schizophrenia
20120 citationsauthor #8
Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia.
201266 citationsauthor #7
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
201230 citationsauthor #4
Motherhood in schizophrenia: an ignored reality
20110 citationsauthor #1
Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study.
201111 citationsauthor #1
Spanish Validation Of the Brief Assessment in Cognition in Schizophrenia (Bacs) in Patients With Schizophrenia and Healthy Controls
201182 citationsauthor #7
Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study.
201124 citationsauthor #8
SPANISH VALIDATION OF THE BACS (BRIEF ASSESSMENT IN COGNITION IN SCHIZOPHRENIA); PERFORMANCE IN PATIENTS AND HEALTHY CONTROLS
20080 citationsauthor #9
Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study.
200714 citationsauthor #4
Spanish Journal of Psychiatry and Mental Health
year unknown0 citationsauthor #8

TIMELINE

2007 14 citations

2008 0 citations

2011 117 citations

2012 96 citations

2013 46 citations

2015 79 citations

2016 1 citations

2017 208 citations

2018 115 citations

2019 87 citations

2020 82 citations

2021 11 citations

2022 3 citations

2023 21 citations

2024 12 citations

2026 0 citations

Unknown 0 citations

G. Safont

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT